At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AVTE Aerovate Therapeutics, Inc.
Market Closed 11-22 16:00:00 EST
2.66
+0.05
+1.92%
盘后2.66
+0.000.00%
16:20 EST
High2.69Low2.59Vol222.03K
Open2.61D1 Closing2.61Amplitude4.02%
Mkt Cap76.81MTradable Cap31.53MTotal Shares28.87M
T/O590.56KT/O Rate1.87%Tradable Shares11.85M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-11
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-08
Calendar of U.S. Earnings Expected in the Week Ahead
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
seekingalpha  ·  11-03
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
BRIEF-Aerovate Therapeutics - Exchange Ratio Assumes Valuation For Aerovate Of $8.0 Million And Valuation For Jade Of $175.0 Million
Reuters  ·  10-31
BRIEF-Aerovate Therapeutics - Exchange Ratio Assumes Valuation For Aerovate Of $8.0 Million And Valuation For Jade Of $175.0 Million
Aerovate Therapeutics - Exchange Ratio Assumes Valuation for Aerovate of $8.0 Million and Valuation for Jade of $175.0 Mln
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics - Exchange Ratio Assumes Valuation for Aerovate of $8.0 Million and Valuation for Jade of $175.0 Mln
Aerovate Therapeutics - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Jade Termination Fee of $2.3 Mln
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Jade Termination Fee of $2.3 Mln
Aerovate climbs on all-stock merger deal with Jade
seekingalpha  ·  10-31
Aerovate climbs on all-stock merger deal with Jade
Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment
Dow Jones  ·  10-31
Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment
BRIEF-Aerovate Therapeutics And Jade Biosciences Announce Merger Agreement
Reuters  ·  10-31
BRIEF-Aerovate Therapeutics And Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics Inc - Tom Frohlich to Lead Combined Company as CEO
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics Inc - Tom Frohlich to Lead Combined Company as CEO
Aerovate Therapeutics Inc - to Declare $65 Million Cash Dividend to Stockholders
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics Inc - to Declare $65 Million Cash Dividend to Stockholders
Aerovate Therapeutics Inc - Stockholders to Own 1.6% of Combined Company
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics Inc - Stockholders to Own 1.6% of Combined Company
Aerovate Therapeutics Inc - Jade Secures $300 Million in Private Investment
THOMSON REUTERS  ·  10-31
Aerovate Therapeutics Inc - Jade Secures $300 Million in Private Investment
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
GlobeNewswire  ·  10-31
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics Board Member Maha Katabi Resigns
TIPRANKS  ·  10-11
Aerovate Therapeutics Board Member Maha Katabi Resigns
Tracking Baker Brothers Portfolio - Q2 2024 Update
seekingalpha  ·  09-11
Tracking Baker Brothers Portfolio - Q2 2024 Update
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)
TIPRANKS  ·  08-13
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-12
Calendar of U.S. Earnings Expected in the Week Ahead
Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown
MT Newswires Live  ·  07-08
Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown

Introduction

Company Name.
Aerovate Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Issue price:
--